1. Background {#sec1}
=============

*Escherichia coli (E. coli)*is one of the most widespread bacteria throughout the world. Some strains of*E. coli* can cause serious illness for humankind \[[@B1]\] including urinary tract infections \[[@B2]--[@B4]\], bloodstream infections \[[@B5]\], skin infection, otitis media \[[@B6], [@B7]\], and diarrhea \[[@B8]\].

*E. coli* resistance to antimicrobials is creating trouble to the healthcare system worldwide \[[@B9], [@B10]\]. This complicates treatment outcomes, increases the cost of treatment, and limits the therapeutic options that contribute to the global spectra of a postantimicrobial age in which some of the most effective drugs lose their efficiency \[[@B11]\]. The bacterium is becoming highly resistant to conventionally used antibiotics (to both the newer and older medicines) as evidenced by many previous studies \[[@B12]--[@B16]\]. Adaptive resistance was supposed to be the main mechanism for the development of resistance including that to lethal doses of the antimicrobials \[[@B17]\].

Antimicrobial resistance of*E. coli* in developing countries including Ethiopia is reported to be one major reason for failure of treatment of infectious diseases \[[@B18]\]. A number of studies conducted in Ethiopia from various clinical settings show increments in the prevalence of antimicrobial resistance patterns of*E. coli* \[[@B6], [@B19], [@B20]\]. However, there is no comprehensive and aggregated nationwide study to show the pattern of antimicrobial resistance in*E. coli*. Hence, the purpose of this meta-analysis was to sum up the available data and to establish the pooled prevalence and antimicrobial resistance of*E. coli* in Ethiopia.

2. Methods {#sec2}
==========

This study was conducted in a similar approach to Eshetie et al. (2016) \[[@B21]\] and according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Checklist \[[@B22]\] ([additional S1](#supplementary-material-1){ref-type="supplementary-material"} file).

2.1. Study Selection {#sec2.1}
--------------------

A systematic literature search was conducted in PubMed and Embase, and also manual search for articles potentially relevant to our study was identified. We built our search strategy by combining the three main arms ([Table 1](#tab1){ref-type="table"}):*E. coli*, drugs-related terms, and Ethiopia.

Among the citations extracted, abstracts were reviewed to retrieve the clinical studies on*E. coli* colonization. Articles that were relevant, by title and abstract, were accessed in full text to determine those that provided sufficient information to be included in our meta-analysis. Finally, the references cited by each eligible study were screened to identify additional articles.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies included in this meta-analysis were those that had extractable data on the prevalence of drug resistance of*E. coli* on a human in Ethiopian hospitals or research centers and were only published from 2007 to 2017 and were only in English language.

2.3. Outcome of Interest {#sec2.3}
------------------------

The main outcome of interest was the prevalence of drug resistance or antimicrobial susceptibility of*E. coli* among the total*E. coli* clinical isolates. The prevalence was calculated by dividing the numbers of resistant*E. coli* isolates by the total number of clinically isolated*E. coli*. As a secondary outcome of interest, we had also calculated the pooled resistance pattern of*E. coli* isolates to specific antibiotics.

2.4. Data Extraction and Assessment of Quality of Study {#sec2.4}
-------------------------------------------------------

Screening by title, abstract, and full text and data extraction were done independently by two authors (Kald Beshir Tuem and Abadi Kahsu Gebre) at each step and Derbew Fikadu Berhe was involved in consensus for discrepancies (if any) between the two authors (Kald Beshir Tuem and Abadi Kahsu Gebre). In cases of insufficient data, the authors reviewed the full text of the article for further information and clarification. The extracted data from each article were summarized into a spreadsheet. References and data for each study were carefully cross-checked to ensure that no overlapping data were present and to maintain the integrity of the meta-analysis. Information extracted from each paper was region, study area, study design, study population, culture specimens, number of*E. coli* isolated, the average percentage of resistant*E. coli*, antimicrobial resistance rate of*E. coli*, and references. With all the articles used in this study being cross-sectional, the score for the quality of the study was assessed using the modified Newcastle-Ottawa scale for the representativeness of sample, appropriateness of sample size, response rate, validity of method, strategy to control confounding factors, reliability of outcome determination, and appropriate statistical analyses. The quality score ([Table 2](#tab2){ref-type="table"}) disagreements were resolved by consensus and a final agreed-upon rating was assigned to each study ([S2](#supplementary-material-1){ref-type="supplementary-material"} file) \[[@B23]\].

2.5. Quality Control {#sec2.5}
--------------------

The quality of eligible studies was checked independently by two authors (Kald Beshir Tuem and Abadi Kahsu Gebre) using a set of predetermined criteria such as research design quality of paper, completeness of extractable information, and employed methods for*E. coli* isolation. The study bias was measured by Begg\'s funnel plot \[[@B24]\]. This study was registered in PROSPERO as follows: PROSPERO 2017: CRD42017070106.

2.6. Data Analysis {#sec2.6}
------------------

A random-effects model was used to determine pooled prevalence, subgroup analysis, and 95% confidence interval (CI) by employing the approach of DerSimonian and Laird \[[@B25]\]. Variances and CIs were stabilized using Freeman-Tukey arc-sine methodology \[[@B26]\]; the reason is that using the standard approach of inverse variance method to calculate pooled prevalence does not work well in meta-analysis of single-arm study because, for studies with small or large prevalence, the inverse variance method causes the variance to become small and the calculated CI may be outside of the range \[[@B27]\]. Heterogeneity of study results was assessed using *I*^2^ test and significant heterogeneity was considered at *p* \< 0.10 and *I*^2^ \> 50% \[[@B25], [@B28]\]. Statistical analyses were performed using Open Meta-Analyst (version 3.13) and Comprehensive Meta-Analysis (version 3.1). In addition, we performed subgroup analyses according to the region of the country and the mechanism of action of the tested drugs to improve the specificity of the assessment.

3. Results {#sec3}
==========

From Embase, PubMed, and manual searching, we found 164 potentially relevant studies, of which 35 were included for analysis ([Figure 1](#fig1){ref-type="fig"}).

The study design of all included articles (35) was cross-sectional study. In these studies, a total of 19,235 study samples participated, from which 2,635*E. coli* strains were isolated. The published studies were from four regions in Ethiopia ([Table 2](#tab2){ref-type="table"}) which include the federal capital city of Ethiopia, Addis Ababa. No report was obtained from other regions in the country (Afar, Benishangul-Gumuz, Gambella, and Somali). Most of the studies indicated that various specimens had been utilized for screening of*E. coli*; particularly multisite swabbing was performed from different parts of the body, including skin, nasal, eye, ear, urethra, throat, vagina, or genital area ([Table 2](#tab2){ref-type="table"}), and other biological fluids like blood, urine, pus, stool, and cerebrospinal fluid (CSF) were taken for test. A total of 2,635*E. coli* strains were isolated from these various sites. The lowest and highest proportions of*E. coli* resistance were reported, respectively, from Bahir Dar (55.20%) and Mekelle (27.50%) cities. The average prevalence of*E. coli* resistance was also noted in different regions of Ethiopia; Addis Ababa region was ranked first (62.55%, 95% CI: 38.28--6.83%), followed by Southern Nations, Nationalities, and Peoples of Ethiopia (58.14%, 95% CI: 48.69--67.58%), Amhara (47.83%, 95% CI: 39.77--55.89%), and Oromia (42.86%, 95% CI: 32.77--52.95%), whereas relatively low magnitude of*E. coli* resistance was reported from Tigray region (27.51%, 95% CI: 16.14--38.88%) (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Subgroup analyses ([Figure 3](#fig3){ref-type="fig"}) were carried out based on the region (Addis Ababa, Amhara, Oromia, SNNP, and Tigray) and the mechanism of action of the drugs (cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, and antimetabolites). A paper-based analysis in our study showed that the overall*E. coli* resistance in Ethiopia was 48.87% (95% CI: 42.17--55.57%) with highest prevalence in the capital city, Addis Ababa, 62.55% (95% CI: 38.28--86.83%) ([Figure 3](#fig3){ref-type="fig"}).

As presented in [Figure 4](#fig4){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}, the pooled prevalence of*E. coli* resistance was 45.38% (95% CI: 33.50--57.27%), and high resistance rates were observed to ampicillin, 83.81% (95% CI: 76.95--90.67%), amoxicillin, 75.79% (95% CI: 64.26--87.32%), tetracycline, 67.18% (95% CI: 58.89--75.47%), trimethoprim-sulfamethoxazole, 57.47% (95% CI: 58.89--75.47%), and cephalothin, 56.69% (95% CI: 33.74--79.64%). A relatively low level of nitrofurantoin resistance was observed, 13.55% (95% CI: 5.83--21.27%).

Comparing the prevalence of*E. coli* resistance among the antibacterial drugs, subgroup analysis ([Figure 5](#fig5){ref-type="fig"}) revealed that the cell wall synthesis inhibitors account for the greatest resistance percentage, 59.37% (95% CI: 36.21--82.53%), and DNA synthesis inhibitors account for the lowest resistance percentage, 26.14% (95% CI: 33.50--57.27%).

There was a high level of heterogeneity by random model methods (*I*^2^ = 97.89%; *p* \< 0.01). Hence, the included studies have been conducted in different study settings, study periods, and study populations, which could have an effect on the heterogeneity of the included studies. The symmetry of funnel plot showed small study bias, which yielded insignificant effect.

4. Discussion {#sec4}
=============

Antibiotic resistance continues to be a major global challenge in the management of bacterial infection. The trouble behind antibiotic resistance is highly marked in undeveloped or developing countries, including Ethiopia, where infectious diseases are highly prevalent \[[@B64]\]. Factors responsible for an increase in rates of antimicrobial resistance include misuse/overuse of antibiotics by healthcare professionals and general public and inadequate surveillance systems due to lack of reliable microbiological techniques leading to the inappropriate prescription of antibiotics \[[@B39]\]. Antimicrobial resistance in*E. coli* has increased worldwide and its susceptibility patterns show substantial variation in different geographical locations \[[@B5]\]. To date, the overall epidemiology and burden of multidrug resistance (MDR) bacteria have not been fully understood, especially in resource-limited countries including Ethiopia \[[@B64], [@B66]\]. To the best of our knowledge, this is the first meta-analysis study conducted to determine the pooled prevalence of*E. coli* prevalence and resistance in Ethiopia. Our result revealed that*E. coli* strains displayed diverse resistance patterns, with percentages varying slightly based on sample type and geographical distribution. Based on the tested antimicrobials, the overall*E. coli* resistance in Ethiopia was nearly 50% (45.38% (95% CI: 33.50--57.27%)).

Developing countries have comparatively higher risk factors associated with MDR strains than the developed ones \[[@B64], [@B67]\]. Resistance to antibacterial agents is a normal evolutionary process for microorganisms, but it is highly aggravated by continuous deployment of antimicrobial drugs in treating infections \[[@B68], [@B69]\]. It is claimed that more than half of drugs are prescribed, sold, or dispensed without following standard protocols, and the situation is more pronounced in developing countries including Ethiopia \[[@B70]\]. Sosa et al. (2010) reported that antibiotic usage in most of the low-income countries is generally unregulated, which is a prime factor for the occurrence of resistant bacterial strains \[[@B64]\]. This implies that antibiotics are being used widely and inappropriately in resource-limited countries including Ethiopia. This may lead to an increase in the occurrence of drug-resistive bacterial strains such as*E. coli*.

In our study, the regional prevalence of*E. coli* resistance was estimated, and the subgroup analysis showed that the highest prevalence of*E. coli* resistance (62.55%) was noted in Addis Ababa city, which was almost two times higher than Tigray region (27.51%). The observed variation might be due to differences in study location, hospital setup, and antimicrobial utilization.

Subgroup analysis also showed that*E. coli* strains exhibited higher resistance with cell wall inhibitors, specifically aminopenicillins (ampicillin and amoxicillin), followed by protein synthesis inhibitors, mainly to tetracycline, and lesser resistance prevalence to nitrofurantoin. In line with our data, globally,*E. coli* strains were reported to be highly resistant to the above-mentioned antibiotics, mainly to aminopenicillins \[[@B71], [@B72]\]. Săndulescu (2016) reported that*E. coli* showed low resistance to nitrofurantoin, which is in line with the present finding.

Moreover, our finding indicated the higher magnitude of*E. coli* resistance. This may imply the need for intervention in prescribing and using antibacterial against*E. coli* infections. Interventional strategies may include creating public awareness, maintaining hand hygiene, applying infection prevention protocols, and maintaining environmental sanitation, which are encouraged for preventing infection. In addition to these, promoting health education, maintaining continuous professional educations, and advocating rational prescribing habits are evidently effective in the minimization of the unwanted use of antibiotics, which in turn decrease selective pressure of resistant strains.

5. Conclusion {#sec5}
=============

In this meta-analysis, the pooled*E. coli* resistance is considerably high.*E. coli* strains were highly resistant to ampicillin but showed lesser resistance to nitrofurantoin. Adopting safety protocols and implementing proper antibiotic prescription policies could be potential interventional strategies to address the emerging resistance of*E. coli*.
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###### 

S1 file: PRISMA 2009 Checklist. We have conducted the meta-analysis according to Moher et al. (2009), "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement." We included all the criteria on the checklist, except in the discussion part; we did not include the limitations of the study related to incomplete retrieval of articles, as we did not face such a problem.

###### 

Click here for additional data file.

###### 

S2 file: Modified Newcastle-Ottawa Scale. This scale had been adapted from Wells et al. (2009), "The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses." We considered the comparability to be controlled if the standard laboratory procedure is described in the articles. Since the outcome of the bacterial sensitivity test is obtained after full growth of the bacterial strains, we assigned one star for the assessment outcomes of all studies.

###### 

Click here for additional data file.

![Flowchart shows selected articles for meta-analysis.](BMRI2018-4536905.001){#fig1}

![Proportion of*E. coli* resistance in different regions of Ethiopia, 2007--2017. Values in parenthesis indicated 95% CI of*E. coli* resistance in different regions of Ethiopia.](BMRI2018-4536905.002){#fig2}

![Subgroup analysis of*E. coli* antibacterial resistance according to regions of Ethiopia.](BMRI2018-4536905.003){#fig3}

![Forest plot of the pooled percentage and confidence interval of*E. coli* resistance to antibacterial drugs in Ethiopia from 2007 to 2017.](BMRI2018-4536905.004){#fig4}

![Subgroup analysis of pooled percentage and confidence interval of*E. coli* resistance to antibacterial drugs according to drug mechanism of action.](BMRI2018-4536905.005){#fig5}

###### 

Searching strategies including search arm and terms used in the study.

      Search arm               Search terms
  --- ------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1   *E. coli*                "*Escherichia coli*" OR *"E. coli"*
  2   Drug and/or resistance   "antibiotic resistance" OR "drug resistance" OR "drug resistance, microbial" OR "drug resistance, microbial" OR "antibacterial resistance" OR "antibiotic resistance" OR "antimicrobial resistance"
  3   Ethiopia                 "Ethiopia"

The word "OR" was used to combine search terms within each arm and the word "AND" was used to connect the three search arms (\#1 AND \#2 AND \#3).

###### 

Summary of 35 studies reporting the prevalence and resistance pattern of *E. coli*in different parts of Ethiopia.

  References                             Region             Study area                             Study period            Study design                                                   Study population                                                                                                         Culture specimens              Study samples   Number of *E. coli* isolated   Average %resistant *E. coli*   NOS quality score out of 7
  -------------------------------------- ------------------ -------------------------------------- ----------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------ --------------- ------------------------------ ------------------------------ ----------------------------
  Abejew et al., 2014 \[[@B29]\]         Amhara             Dessie                                 January to March 2012   RCS                                                            Test results of patients diagnosed with UTI                                                                              Urine                          2486            410                            51.8                           6
  Kibret and Abera, 2014 \[[@B30]\]      Dessie             ---                                    R                       Patients                                                       Mid-stream morning urine                                                                                                 1404                           203             53.2                           6                              
  Kibret and Abera, 2011 \[[@B31]\]      Dessie             ---                                    R                       Patients                                                       Urine, ear discharge, pus swab from wounds, and eye discharge                                                            3,149                          446             44.2                           6                              
  Azene and Beyene, 2011 \[[@B32]\]      Dessie             ---                                    R                       Patents with wound infections                                  Wound swab                                                                                                               599                            82              49.8                           6                              
  Alebachew et al., 2016 \[[@B33]\]      Gondar             March 1 to May 2, 2013                 CS                      HIV patients                                                   Blood                                                                                                                    100                            01              44.4                           7                              
  Alemu et al., 2012 \[[@B34]\]          Gondar             March 22 to April 30, 2011             CS                      Pregnant women attending ANC                                   Urine                                                                                                                    385                            19              29.2                           7                              
  Wondimeneh et al., 2014 \[[@B35]\]     Gondar             January to May 2013                    CS                      Fistula patients                                               "Clean-catch" mid-stream urine specimen                                                                                  53                             6               59.3                           6                              
  Wondimu et al., 2013 \[[@B36]\]        Gondar             December 2011 to June 2012             CS                      Blood donated from donors at blood bank                        blood                                                                                                                    137                            2               0.7                            7                              
  Eshetie et al., 2015 \[[@B37]\]        Gondar             February to May 2014                   CS                      UTI-suspected patients                                         Urine                                                                                                                    442                            112             48.0                           4                              
  Tiruneh et al., 2014 \[[@B38]\]        Gondar             September 1, 2011, to June 30, 2012    CS                      UTI-suspected patients                                         Urine                                                                                                                    284                            120             68.0                           4                              
  Eshetie et al., 2016 \[[@B39]\]        Gondar             February to June 2014                  CS                      Patients with UTI                                              Urine                                                                                                                    446                            112             38.8                           6                              
  Mulu et al., 2017 \[[@B40]\]           Debre Markos       January 2015                           R                       Patients                                                       Pus/swab from wound, urine, ear discharge, blood, stool, urethral or cervical discharge, nasal or throat swab, and CSF   575                            39              31.5                           6                              
  Abera and Kibret, 2014 \[[@B41]\]      West Gojjam        November 2009 to February 2010         CS                      Adult patients who underwent trachomatous trichiasis surgery   Conjunctival swabs                                                                                                       1413                           20              26.5                           5                              
  Adugna et al., 2015 \[[@B42]\]         Bahir Dar          December 2011 to February 2012         CS                      Children below five years of age with acute diarrhea           Stool sample                                                                                                             422                            204             42.8                           7                              
  Demilie et al., 2012 \[[@B43]\]        Bahir Dar          October 2010 to January 2011           CS                      Pregnant women                                                 Clean-catch urine                                                                                                        367                            16              41.7                           4                              
  Derbie et al., 2017 \[[@B44]\]         Bahir Dar          January 2015                           R                       Patients                                                       Urine                                                                                                                    446                            72              55.3                           5                              
  Melaku et al., 2012 \[[@B45]\]         Bahir Dar          April to August 2010                   CS                      Patients                                                       Urine                                                                                                                    1254                           33              87.8                           6                              
  Mulu et al., 2012 \[[@B46]\]           Bahir Dar          October 2010 to January 2011           CS                      Patients                                                       Wound swab and venous blood samples                                                                                      294                            8               53.1                           6                              
  Wondemagegn et al., 2015 \[[@B47]\]    Bahir Dar          May to November 2013                   CS                      Women of reproductive age                                      Vaginal swab                                                                                                             409                            105             50.5                           7                              
                                                                                                                                                                                                                                                                                                                                                                                                                                
  Dereje et al., 2017 \[[@B48]\]         Central Ethiopia   Addis Ababa                            February to May 2015    CS                                                             Fistula patients                                                                                                         Clean-catch mid-stream urine   210             65                             38.2                           7
  Dessie et al., 2016 \[[@B49]\]         Addis Ababa        October 2013 and March 2014            CS                      Surgical site infected patients                                Wound swab                                                                                                               107                            24              68.4                           6                              
  Desta et al., 2016 \[[@B50]\]          Addis Ababa        December 2012                          CS                      All age groups patients                                        Fecal samples/swabs                                                                                                      267                            235             83.0                           7                              
  Mamuye, 2016 \[[@B51]\]                Addis Ababa        August 2013 to January 2014            CS                      Outpatient and inpatient and pregnant women                    Mid-urine samples                                                                                                        424                            53              52.2                           5                              
  Legese et al., 2017 \[[@B52]\]         Addis Ababa        January to March 2014                  CS                      Septicemia and UTI-suspected patients                          Blood and urine                                                                                                          322                            6               72.9                           6                              
                                                                                                                                                                                                                                                                                                                                                                                                                                
  Ramos et al., 2014 \[[@B53]\]          Oromia             West Arsi                              July to December 2013   CS                                                             Leprosy patients                                                                                                         Pus produced by ulcer          68              17                             35.8                           5
  Derese et al., 2016 \[[@B54]\]         Dire Dawa          February 18, 2015, to March 25, 2015   CS                      Pregnant women                                                 Urine specimens                                                                                                          186                            9               34.4                           6                              
  Beyene and Tsegaye, 2011 \[[@B55]\]    Jimma              April to June 2010                     CS                      UTI cases patients                                             Urine                                                                                                                    228                            7               27.1                           5                              
  Debalke et al., 2014 \[[@B56]\]        Jimma              September to December 2012             CS                      HIV/AIDS patients                                              Urine                                                                                                                    481                            31              36.6                           7                              
  Mama et al., 2014 \[[@B57]\]           Jimma              May to September 2013                  CS                      Patients with wound infection                                  Wound swab                                                                                                               150                            29              61.6                           6                              
  Mulualem, 2012 \[[@B58]\]              Jimma              February to March 2007                 CS                      Inpatients and outpatients                                     Urine, sputum, stool, and wound                                                                                          359                            67              45.7                           6                              
  Zenebe et al., 2011 \[[@B59]\]         Jimma              October 27, 2009, to March 26, 2010    CS                      Febrile patients                                               Venous blood                                                                                                             260                            4               25.0                           6                              
                                                                                                                                                                                                                                                                                                                                                                                                                                
  Nigussie and Amsalu, 2017 \[[@B60]\]   SNNP               Hawassa                                June to October 2014    CS                                                             Diabetic patients                                                                                                        Mid-stream urine               240             11                             47.7                           7
  Amsalu et al., 2016 \[[@B61]\]         Hawassa            January 2012 to December 2014          RCS                     Patients registered at microbiology lab book                   Pus, ear discharge, nasal swab, urine, genital swab, CSF, and stool                                                      510                            35              64.0                           7                              
  Tadesse et al., 2014 \[[@B62]\]        Hawassa            March to September 2012                CS                      Pregnant women attending ANC                                   Mid-stream urine                                                                                                         244                            16              56.3                           6                              
                                                                                                                                                                                                                                                                                                                                                                                                                                
  Wasihun et al., 2015 \[[@B63]\]        Tigray             Mekelle                                March to October 2014   PCS                                                            Febrile patients                                                                                                         Venous blood                   514             16                             27.5                           6
                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                          *Total*                                                                                                                  *19,235*                       *2,635*                                                                       

ANC: antenatal clinic, CSF: cerebrospinal fluid, CS: cross-sectional, PCS: prospective cross-sectional, R: retrospective review of culture, RCS: retrospective cross-sectional, SNNP: Southern Nations, Nationalities, and Peoples, UTI: urinary tract infection, ---: no data.

###### 

Percentage of pooled antibacterial resistance rates of *E. coli* in Ethiopia, 2007--2017.

  Studies                                Antibacterial                                                                                                                   
  -------------------------------------- --------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Abejew et al., 2014 \[[@B29]\]         84.6            80.0    \-\--   42.3    46.9    82.2    64.5    49.0    94.4    34.0    20.0    28.3    13.3    10.4    \-\--   75.8
  Abera and Kibret, 2014 \[[@B41]\]      \-\--           \-\--   \-\--   \-\--   40      25      \-\--   35      \-\--   40      \-\--   4       \-\--   \-\--   \-\--   15
  Adugna et al., 2015 \[[@B42]\]         \-\--           86.8    47.5    \-\--   \-\--   76      \-\--   36.2    \-\--   37.2    \-\--   6.9     \-\--   \-\--   9.3     \-\--
  Alebachew et al., 2016 \[[@B33]\]      \-\--           100     100     \-\--   0       100     \-\--   0       \-\--   0       \-\--   0       \-\--   0       \-\--   100
  Alemu et al., 2012 \[[@B34]\]          100             100     36.8    \-\--   0       52.6    \-\--   0       \-\--   5.3     \-\--   0       \-\--   \-\--   0       26.3
  Beyene and Tsegaye, 2011 \[[@B55]\]    100             100     \-\--   \-\--   0       28.6    \-\--   0       \-\--   0       \-\--   14.3    0       0       \-\--   28.6
  Debalke et al., 2014 \[[@B56]\]        \-\--           88      \-\--   \-\--   4       \-\--   \-\--   0       \-\--   \-\--   \-\--   \-\--   52      0       16      96
  Demilie et al., 2012 \[[@B43]\]        75              81.7    37.5    \-\--   \-\--   68.8    \-\--   37.5    \-\--   31.2    18.8    18.8    43.8    6.3     25      56.2
  Derbie et al., 2017 \[[@B44]\]         \-\--           89.1    78.6    \-\--   \-\--   66.1    \-\--   \-\--   \-\--   27.6    \-\--   64.4    \-\--   25      27      64.5
  Dereje et al., 2017 \[[@B48]\]         \-\--           \-\--   21.6    \-\--   24.6    \-\--   \-\--   32.2    \-\--   53.8    \-\--   56.9    \-\--   40      \-\--   \-\--
  Derese et al., 2016 \[[@B54]\]         77.8            77.8    \-\--   \-\--   0       66.7    \-\--   11.1    \-\--   0       \-\--   11.1    44.4    44.4    \-\--   11.1
  Dessie et al., 2016 \[[@B49]\]         \-\--           95.8    70.8    \-\--   83.3    83.3    \-\--   25      \-\--   54.2    \-\--   66.7    \-\--   \-\--   \-\--   \-\--
  Desta et al., 2016 \[[@B50]\]          \-\--           \-\--   93      98      \-\--   \-\--   \-\--   \-\--   \-\--   63      \-\--   78      \-\--   \-\--   \-\--   \-\--
  Eshetie et al., 2015 \[[@B37]\]        \-\--           92.9    60.7    \-\--   17.9    53.6    \-\--   64.3    \-\--   57.1    \-\--   10.7    25      \-\--   \-\--   50
  Kibret and Abera, 2014 \[[@B30]\]      87.3            \-\--   \-\--   56.9    33.9    80.1    61      37.4    93.7    24.5    \-\--   34.1    \-\--   3.8     \-\--   72.1
  Kibret and Abera, 2011 \[[@B31]\]      86              \-\--   \-\--   59.5    37.4    72.4    \-\--   35.3    89.4    13      \-\--   19.9    \-\--   3.6     6.5     62.9
  Azene and Beyene, 2011 \[[@B32]\]      85.0            \-\--   \-\--   64.7    66.7    71.4    33.3    36.1    51.9    14.4    \-\--   7.7     \-\--   \-\--   \-\--   67.1
  Mama et al., 2014 \[[@B57]\]           \-\--           100     \-\--   100     62      79      44.8    65.5    \-\--   51.7    \-\--   34      41      \-\--   44.8    55
  Mamuye, 2016 \[[@B51]\]                75.5            79.2    \-\--   32.1    45.3    83.0    71.7    30.2    \-\--   22.6    \-\--   54.7    73.6    20.8    67.9    22.6
  Melaku et al., 2012 \[[@B45]\]         85.7            100     \-\--   \-\--   \-\--   81.6    \-\--   83.7    \-\--   \-\--   \-\--   \-\--   \-\--   \-\--   \-\--   \-\--
  Mulu et al., 2017 \[[@B40]\]           25              33.3    \-\--   \-\--   3.3     75      75      13      0       69.6    \-\--   18.2    \-\--   \-\--   23.1    11.1
  Mulualem et al., 2012 \[[@B58]\]       86              86      70.1    \-\--   9       73.1    \-\--   35.8    \-\--   3       \-\--   20.9    \-\--   \-\--   16.4    56.7
  Mulu et al., 2012 \[[@B46]\]           90              78      \-\--   \-\--   55.6    66.7    66.7    0       \-\--   44.4    44.4    44.4    66.7    22.2    44.4    67
  Nigussie and Amsalu, 2017 \[[@B60]\]   \-\--           100     36.4    \-\--   63.6    \-\--   \-\--   \-\--   \-\--   72.7    \-\--   18.2    \-\--   0       9.1     81.8
  Ramos et al., 2014 \[[@B53]\]          64.7            70.6    5.9     \-\--   5.9     41.2    29.4    35.3    41.2    11.8    \-\--   29.4    \-\--   \-\--   \-\--   58.8
  Wasihun et al.2015 \[[@B63]\]          \-\--           \-\--   6.7     \-\--   60      \-\--   40      \-\--   \-\--   13.3    \-\--   6.7     \-\--   26.7    60      6.7
  Wondimeneh et al., 2014 \[[@B35]\]     50              66.7    \-\--   \-\--   50      100     \-\--   16.7    \-\--   66.7    \-\--   50      \-\--   \-\--   66.7    66.7
  Wondimu et al., 2013 \[[@B36]\]        \-\--           33.3    0       \-\--   0       0       0       0       0       0       \-\--   33.3    \-\--   \-\--   \-\--   0
  Zenebe et al., 2011 \[[@B59]\]         0               100     \-\--   0       0       75      \-\--   100     \-\--   75      \-\--   0       0       \-\--   \-\--   100
  Amsalu1 et al., 2016 \[[@B60]\]        \-\--           100     26.1    \-\--   45.7    \-\--   \-\--   64.3    \-\--   60.6    \-\--   56.2    \-\--   \-\--   68.8    90
  Tadesse et al., 2014 \[[@B62]\]        \-\--           68.8    \-\--   \-\--   \-\--   \-\--   \-\--   \-\--   \-\--   43.8    \-\--   \-\--   \-\--   \-\--   18.8    81.2
  Tiruneh et al., 2014 \[[@B38]\]        87.5            83.3    \-\--   \-\--   \-\--   79.2    \-\--   58.3    \-\--   44.2    \-\--   46.7    \-\--   \-\--   \-\--   76.7
  Legese et al., 2017 \[[@B52]\]         100             \-\--   100     \-\--   \-\--   83.3    \-\--   66.7    \-\--   66.7    \-\--   \-\--   \-\--   0       66.7    100
  Eshetie et al., 2016 \[[@B39]\]        \-\--           98.2    42      \-\--   \-\--   43.8    \-\--   54.5    \-\--   52.7    \-\--   0.9     17      \-\--   \-\--   64.3
  Wondemagegn et al., 2015 \[[@B47]\]    80              73.3    \-\--   \-\--   \-\--   73.3    \-\--   \-\--   \-\--   26.7    \-\--   20      \-\--   \-\--   20      60

AMC: amoxicillin-clavulanic acid, AML: amoxicillin, AMP: ampicillin, C: chloramphenicol, CIP: ciprofloxacin, CN: gentamicin, CRO: ceftriaxone, DO: doxycycline, E: erythromycin, F: nitrofurantoin, K: kanamycin, KF: cephalothin, NA: nalidixic acid, NOR: norfloxacin, SXT: trimethoprim/sulfamethoxazole, TE: tetracycline, \-\--: not done.

[^1]: Academic Editor: Giovanni Mariscalco
